Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2025-03-31 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于为控股子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding guarantees provided for loans and supplier payments by its controlling subsidiaries. It includes extensive financial data of the subsidiaries, guarantee amounts, shareholder information, and risk warnings. The document is an official announcement about the company's financing-related guarantees and risk disclosures, not a full financial report or audit report. It does not contain comprehensive financial statements or management discussion and analysis but focuses on capital/financing updates related to guarantees. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a brief notice or report publication announcement but a substantive update on financing activities.
2025-03-31 Chinese
关于2025年度提供财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of financial assistance to its subsidiaries for the fiscal year 2025. It includes specifics about the amounts, recipients, terms, and risk analysis of the financial support. The document is an official announcement about financing activities, including loans and guarantees, rather than a financial report or earnings release. It does not contain comprehensive financial statements or quarterly/yearly financial results but focuses on capital provision and related corporate actions. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (7,866 characters) and content confirm it is a substantive announcement rather than a brief notice or a report publication announcement.
2025-03-31 Chinese
关于召开2025年第一次临时股东大会通知的公告
Regulatory Filings Classification · 95% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting (临时股东大会) of Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, registration details, and proxy authorization. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is 3735 characters, which is relatively short and consistent with a meeting notice rather than a full report. There is no indication that this is a report itself or a transcript, but rather a formal announcement of the meeting and voting details. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or proxy statement, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting and voting process without actual voting results or proxy solicitation materials. Given the specificity of the content and the absence of voting results or proxy materials, Regulatory Filings (RNS) is the most appropriate category.
2025-03-31 Chinese
第九届董事局第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 22nd meeting of the 9th Board of Directors of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, voting results, and specific agenda items such as financial assistance, guarantees, bank credit applications, and convening a shareholders' meeting. The document does not contain financial statements or detailed financial data but rather reports on board decisions and approvals. It is not a full annual or interim report, nor an earnings release or audit report. The content focuses on board meeting resolutions and approvals, which fits the category of Board/Management Information (MANG). The document length is about 2531 characters, which is consistent with a meeting resolution announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2025-03-31 Chinese
监事会关于第九届监事会第十八次会议相关事项的意见
Board/Management Information Classification · 90% confidence The document is a statement from the Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. regarding opinions on matters discussed at the 18th meeting of the 9th Supervisory Board. It focuses on the Supervisory Board's approval and opinions on guarantees provided by the company to subsidiaries and related parties. There is no indication of financial statements, audit results, or detailed financial data. The content is related to board-level oversight and approvals, specifically from the Supervisory Board, which is part of management/governance structure. Therefore, the document fits best under Board/Management Information (MANG), as it announces management-level opinions and approvals on company matters.
2025-03-31 Chinese
第九届监事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 9th Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, voting results, and references related announcements published elsewhere. The content focuses on internal supervisory board decisions regarding financial assistance and guarantees, with no financial statements or detailed financial data included. The document is an official announcement of board/management decisions rather than a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it does not contain financial data or audit information, so it is not an Annual Report or Audit Report. It is not a regulatory filing or report publication announcement since it contains substantive meeting resolution details.
2025-03-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.